Regeneron Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75886F1075

SecurityREGN / Regeneron Pharmaceuticals, Inc.
InstitutionBlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I
Latest Disclosed Ownership241 shares
Latest Disclosed Value $ 126,525
BlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I reports 40.94% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On August 28, 2025 - BlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I filed a NPORT-P form disclosing ownership of 241 shares of Regeneron Pharmaceuticals, Inc. (US:REGN) valued at $126,525 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 171 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 40.94% during the quarter. The current value of the position is $181,128 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-28 2025-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 241 70 40.94 127 16.67 0.0833
2025-05-27 2025-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 171 0 0.00 108 -10.74 0.0724
2025-02-27 2024-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 171 77 81.91 122 23.47 0.0753
2024-11-26 2024-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 94 -10 -9.62 99 -10.09 0.0607
2024-08-27 2024-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 104 -164 -61.19 109 -57.59 0.0661
2024-05-28 2024-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 268 0 0.00 258 9.36 0.1507
2024-02-27 2023-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 268 -15 -5.30 235 1.29 0.1412
2023-11-22 2023-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 283 105 58.99 233 82.68 0.1401
2023-08-25 2023-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 178 -157 -46.87 128 -53.82 0.0748
2023-05-26 2023-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 335 0 0.00 275 14.11 0.1626
2023-02-24 2022-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 335 -74 -18.09 242 -14.23 0.1388
2022-11-28 2022-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 409 -28 -6.41 282 8.91 0.1654
2022-08-26 2022-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 437 -37 -7.81 258 -22.05 0.1450
2022-05-25 2022-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 474 125 35.82 331 50.45 0.1670
2022-02-25 2021-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 349 30 9.40 220 13.99 0.1026
2021-11-26 2021-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 319 127 66.15 193 80.37 0.0884
2021-08-24 2021-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 192 9 4.92 107 24.42 0.0487
2021-05-25 2021-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 183 -96 -34.41 87 -35.82 0.0395
2021-02-24 2020-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 279 43 18.22 135 1.52 0.0603
2020-11-24 2020-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 236 -84 -26.25 132 -33.67 0.0625
2020-08-24 2020-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 320 -138 -30.13 200 -10.76 0.0956
2020-05-26 2020-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 458 100 27.93 224 66.42 0.1101
2020-02-25 2019-12-31 NP Regeneron Pharmaceuticals EC 75886F107 358 255 247.57 134 378.57 0.0569
2019-11-25 2019-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 103 103 29 0.0122
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.